Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: Results of clinical testing in nonpatient volunteers

Investigative Radiology

Volumn 35, Issue 1, 2000, Pages 1-7

  Spinazzi, Alberto ^a   Ceriati, Simona ^a   Pianezzola, Paola ^a   Lorusso, Vito ^a   Luzzani, Franco ^a   Fouillet, Xavier ^b   Alvino, Simonetta ^a   Rummeny, Ernst J ^c  

^a Bracco SpA   (Italy)

^b Bracco Suisse SA   (Switzerland)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

BR21; Iodinated contrast agent; Iomeprol; Liposomes; Pharmacokinetics

Indexed keywords

BR 21; IODINATED CONTRAST MEDIUM; IOMEPROL; LIPOSOME; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LIVER DISEASE; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREMOR; VERTIGO;

EID: 0033976947     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200001000-00001     Document Type: Article

References (17)

1. Baron RL. Understanding and optimizing use of contrast material for CT of the liver. AJR 1994;163:323-331.
2. Small WC, Nelson RC, Bernardino ME, Brummer LT. Contrast-enhanced spiral CT of the liver: Effect of different amounts and injection rates of contrast material on early contrast enhancement. Am J Roentgenol 1994;163:87-92.
3. Baron R. Detection of liver neoplasms: Techniques and outcomes. Abdom Imaging 1994;19:320-324.
4. Burgener FA, Hamlin DJ. Contrast enhancement of hepatic tumors in CT: Comparison between bolus and infusion techniques. AJR 1983;140:291-295.
5. Garcia PA, Bonaldi VM, Bret PM, et al. Effect of rate of contrast medium injection on hepatic enhancement at CT. Radiology 1996; 199:185-189.
6. Kopka L, Rodenwaldt J, Fischer U, et al. Dual-phase helical CT of the liver: Effects of bolus tracking and different volumes of contrast material. Radiology 1996;201:321-326.
7. Graf O, Gazelle GS, Kreuzer S, et al. Enhancement of hepatic parenchyma, aorta, and portal vein in helical CT: Comparison of iodixanol and iopromide. AJR 1997;168:213-217.
8. Heiken JP, Weyman PJ, Lee JK, et al. Detection of focal hepatic masses: Prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989;171:47-51.
9. Helmberger H III, Bautz WA, Fink U, et al. Will spiral CT during arterial portography change the staging of disease in patients with liver metastases? Review after 150 examinations. Radiology 1994; 193:274.
10. Spinazzi A, Ceriati S, Lorusso V, et al. Safety and pharmacokinetics of BR21, a liver-specific CT agent, in healthy volunteers. Acad Radiol 1998;5 (Suppl 1):S20-22.
11. Lorusso V, Poggesi I, Dal Fiume D, Tirone P. High-performance liquid chromatography assay of iomeprol in plasma and urine. J Chromatogr Biomed Appl 1990;525:401-409.
12. Department of Health and Human Services (DHHS). COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms), 3rd ed. Rockville, MD: DHHS, FDA, 1989.
13. Rosati G. Clinical pharmacology of iomeprol. Eur J Radiol 1994;18: S51-S60.
14. Leander P, Höglund P, Kloster Y, Børseth A. New liposomal liver-specific contrast agent for CT: First human phase I clinical trial assessing efficacy and safety. Acad Radiol 1998;5(Suppl 1):S6-S8.
15. Foley DW. Dynamic hepatic CT. Radiology 1989;170:617-622.
16. Kemmerer SR, Mortele KJ, Ros PR. CT scan of the liver. Radiol Clin North Am 1998;36:247-260.
17. Petersein J, Franke B, Fouillet X, Hamm B. Evaluation of liposomal contrast agents for liver CT in healthy rabbits. Invest Radiol 1999; 34:401-409.